BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Carb-X
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200807T100000
DTEND;TZID=America/New_York:20200807T150000
DTSTAMP:20260403T194244
CREATED:20200720T163544Z
LAST-MODIFIED:20200720T163544Z
UID:4158-1596794400-1596812400@carb-x.org
SUMMARY:Longitude Prize Sprint Workshop 1 - Navigating MedTech Regulation Pathways in Developed and Emerging Markets
DESCRIPTION:In July 2020\, the Longitude Prize is launching the Longitude Prize Sprint Programme. The Sprint programme is free and will consist of a mix of Sprint Workshops and Sprint 1:1 Expert Support and is perfect for people and teams working in the field of AMR diagnostic test development. The Longitude Prize will be running three Sprint Workshop webinars from July to November 2020. The Sprint Workshops (virtual webinars) are open to all Longitude Prize Competitors\, along with diagnostic test developers who are looking for technical advice and support for regulatory pathways\, finance and investment\, and manufacture and distribution strategies.\n\n\nLongitude Prize Sprint Workshop 1 – Navigating MedTech Regulation Pathways in Developed and Emerging Markets \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMedtech product development and commercialisation for devices and diagnostics is a complex process and has a long gestation period. There are many uncertainties that Medtech product development has to navigate especially during technology development and validation stages of product development as well as being able to meet regulatory standards. Successful navigation of the regulatory maze is important in product development roadmap. \nThere are subtle and distinct variations in regulatory standards for Medtech products across different geographies especially between developed and developing countries. Another layer of complexity is the continuous change in regulatory landscapes both in mature and evolving markets across the world. \nThe workshop (virtual webinar)\, as part of the Longitude Prize Sprint programme\, will draw upon insights from experts in Medtech regulation and address the nuances of regulation in different geographies which will guide Medtech companies in their product development strategies. \n\nTo learn more\, click here. 
URL:https://carb-x.org/event/longitude-prize-sprint-workshop-1-navigating-medtech-regulation-pathways-in-developed-and-emerging-markets/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200709T030000
DTEND;TZID=America/New_York:20200709T043000
DTSTAMP:20260403T194244
CREATED:20200330T142214Z
LAST-MODIFIED:20200422T140818Z
UID:3939-1594263600-1594269000@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study
DESCRIPTION:Speakers: \n\nAnand Anandkumar\, Co-founder and CEO Bugworks Research Inc (India)\nKamini Walia\, Program Officer\, ICMR-AMR Initiative (India) \n\nModerator: François Franceschi\, GARDP  \nIn this webinar\, Anand Anandkumar and Kamini Walia will discuss: \n\nWhy is India one of the hotbeds of the AMR problem? Latest statistics of growing drug resistance etc.\nInitiatives of the Indian Government to curb the AMR problem\nAntimicrobial R&D landscape in India – a vibrant ecosystem supporting innovation in AMR diagnosis\, prevention and therapeutics\nFledgling antimicrobial clinical trial networks – could trials out of India play a significant role in gaining global regulatory approvals?\nChanging regulatory environment to enable accelerated approvals for antimicrobial products\n\nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 5 May 2020\, 9:00-10:30 am CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-the-challenges-and-opportunities-for-antimicrobial-rd-in-low-and-middle-income-countries-india-case-study/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200630T110000
DTEND;TZID=America/New_York:20200630T123000
DTSTAMP:20260403T194244
CREATED:20200406T155840Z
LAST-MODIFIED:20200422T140757Z
UID:3950-1593514800-1593520200@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Clinical development of antimicrobials – Phase 1 development challenges
DESCRIPTION:Speaker: Markus Zeitlinger\, Head of Department of Clinical Pharmacology\, Medical University of Vienna (Austria) \nModerator: Markus Heep \nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 30 June\, 17:00-18:30 CEST. Find your time zone here.
URL:https://carb-x.org/event/live-webinar-gardp-revive-clinical-development-of-antimicrobials-phase-1-development-challenges/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200625T110000
DTEND;TZID=America/New_York:20200625T121500
DTSTAMP:20260403T194244
CREATED:20200601T144452Z
LAST-MODIFIED:20200601T144452Z
UID:4059-1593082800-1593087300@carb-x.org
SUMMARY:JLABS Webinar: Raising Capital: A Legal Primer
DESCRIPTION:Having a clear strategy for raising growth capital and understanding the evolution and dynamic of investment deals are essential for the long-term health of your business. Join JLABS\, Allen & Overy and O’Melveny to learn more and discuss key issues such as: \n\nKey points in growth capital deals\nEvolution of deal dynamics\nBoard seats\nGovernance structure\nEconomic terms\nExit terms\n\nTo learn more\, click here.\n\nThis program is part of the Johnson & Johnson Innovation – JLABS Legal Webinar Series for life science entrepreneurs\, together with Allen & Overy and O’Melveny. You can register for other webinars in the series by visiting this page.
URL:https://carb-x.org/event/jlabs-webinar-raising-capital-a-legal-primer/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200609T120000
DTEND;TZID=America/New_York:20200609T130000
DTSTAMP:20260403T194244
CREATED:20200601T144305Z
LAST-MODIFIED:20200601T144305Z
UID:4058-1591704000-1591707600@carb-x.org
SUMMARY:JLABS Webinar: Pulse Check-Today's Funding Landscape
DESCRIPTION:Today’s current crisis has changed the mindset of many industry strategic partners\, investors and overall stakeholders. From pivoting investment priorities\, to identifying new areas of innovation\, the investor landscape is constantly shifting. \nFor small to medium sized biotechs\, it can be hard to keep up with promised milestones while also planning and anticipating the future of their companies. How could companies be preparing for not only the short-term but for years to come? What should be prioritized in the coming months? Who is still investing? How can they find the right partners for them as they move forward? \nJoin JLABS as we welcome members of Johnson and Johnson Development Corp.\, and other industry investors to: \n\n\n\n\n\n\n\n\n\nShare how they are planning for the future and pivoting in the current crisis\nWhat they believe companies should be prioritizing\nHow bio-techs could stay connected with their current and potential stakeholders\nWhere they could find the right resources and investment opportunities\, and overall gain a pulse check on the investor community\n\nTo learn more\, click here.
URL:https://carb-x.org/event/jlabs-webinar-pulse-check-todays-funding-landscape/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200609T110000
DTEND;TZID=America/New_York:20200609T123000
DTSTAMP:20260403T194244
CREATED:20200330T142524Z
LAST-MODIFIED:20200422T140732Z
UID:3943-1591700400-1591705800@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations
DESCRIPTION:Speaker: Vincent H. Tam\, Professor\, University of Houston College of Pharmacy (USA) \nModerator: Shampa Das\, Senior Lecturer\, Centre of Excellence in Infectious Diseases Research\, University of Liverpool (UK)  \nIn this webinar\, Vincent H. Tam will present on his work looking at studying PK/PD in fixed dose beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations. \nTopics discussed will include: \n\nUnderstanding the inherent challenges associated with PK/PD of BL/BLI combinations\nDemonstrating new approaches to gain useful insights from preclinical PK/PD models\n\nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 9 June 2020\, 17:00-18:30 CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-test-tube-to-patient-pk-pd-of-fixed-dose-beta-lactam-beta-lactamase-inhibitor-combinations/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200529T100000
DTEND;TZID=America/New_York:20200529T113000
DTSTAMP:20260403T194244
CREATED:20200527T163340Z
LAST-MODIFIED:20200527T163340Z
UID:4052-1590746400-1590751800@carb-x.org
SUMMARY:Live Webinar: o2h ventures 6th ChaiTime Webinar Registration
DESCRIPTION:Join us on Friday\, May 29 @ 3:00 PM BST (10:00 AM EST / 7.30 PM IST) for our the sixth o2h ventures ChaiTime webinar on ‘Antibiotic Resistance – The fight for humanity’. \nErin Duffy\, Chief of R&D\, CARB-X \, will chair the 6th o2h ventures ChaiTime discussion on drug resistance and lessons to be learned fron the COVID-19 pandemic. \nClick Here to Register for the Webinar. \nWebinar Chair: \nErin Duffy\, Chief of R&D @ CARB-X \nPanelists and Speakers: \nKen Bradley\, Global Head\, Infectious Disease Discovery at Roche pharmaceutical Research and Early Development (pRED) \nAnkit Mahadevia\, CEO of NASDAQ listed\, Spero Therapeutics \nPaul Finn\, CEO of Oxford University Spinout\, Oxford Drug Design \nAjay Mistry\, CEO of AI and antibiotics discovery start-up\, Oppilotech
URL:https://carb-x.org/event/live-webinar-o2h-ventures-6th-chaitime-webinar-registration/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200528T120000
DTEND;TZID=America/New_York:20200528T130000
DTSTAMP:20260403T194244
CREATED:20200504T145415Z
LAST-MODIFIED:20200504T145415Z
UID:3997-1590667200-1590670800@carb-x.org
SUMMARY:Live Webinar – CARB-X - How to Prepare for an FDA Pre-IND Meeting: Planning for Success
DESCRIPTION:Speakers: \nCarmella Moody\, Regulatory Program Director\, RTI International \nMichael Bevilacqua\, M.D.\, Ph.D.\, Chief Executive Officer and Chief Science Officer\, Amicrobe Inc. \nIn this webinar\, Carmella Moody and Michael Bevilacqua will help product developers understand how best to prepare for pre-IND meetings to ensure maximum results. \nCarmella Moody has many years experience supporting and preparing companies for pre-IND meetings. Michael Bevilacqua\, who worked with CARB-X to prepare for his company’s recent pre-IND meeting\, will discuss his positive experience and lessons learned.  Everyone is welcome to join. A recording of the webinar will be available for those who cannot attend the live broadcast. \nPresentations will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on May 28\, 12:00 to 13:00 ET (find your time zone here).
URL:https://carb-x.org/event/live-webinar-carb-x-how-to-prepare-for-an-fda-pre-ind-meeting-planning-for-success/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200519T110000
DTEND;TZID=America/New_York:20200519T123000
DTSTAMP:20260403T194244
CREATED:20200422T141057Z
LAST-MODIFIED:20200422T141057Z
UID:3982-1589886000-1589891400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Assay development for measuring antibiotic accumulation in Gram-negative bacteria
DESCRIPTION:Speakers: \n\nJessica Blair\, Institute of Microbiology and Infection\, University of Birmingham (UK)\nMark Brönstrup\, Department of Chemical Biology\, Helmholtz Centre for Infection Research (Germany)\nDavid A. Six\, Venatorx Pharmaceuticals\, Inc. (US)\n\nModerator: Alice Erwin\, Erwin Consulting LLC (US) \nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-assay-development-for-measuring-antibiotic-accumulation-in-gram-negative-bacteria/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200512T110000
DTEND;TZID=America/New_York:20200512T123000
DTSTAMP:20260403T194244
CREATED:20200330T142407Z
LAST-MODIFIED:20200422T140709Z
UID:3941-1589281200-1589286600@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Probability of target attainment analyses for dose selection in antimicrobial drug development
DESCRIPTION:Speaker: Shampa Das\, Senior Lecturer\, Centre of Excellence in Infectious Diseases Research\, University of Liverpool (UK)  \nModerator: Vincent H. Tam\, Professor\, University of Houston (US)  \nIn this webinar\, Shampa Das will give an overview of her work in studying the PK/PD and probability of target attainment for dose selection. \nTopics discussed will include: \n\nAn overview of what is meant by the probability of target attainment (PTA)\nHow it is calculated and what data is used for this\nHow PTA is used for decision making during drug development\n\nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 12 May 2020\, 17:00-18:30 CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-probability-of-target-attainment-analyses-for-dose-selection-in-antimicrobial-drug-development/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200428T110000
DTEND;TZID=America/New_York:20200428T123000
DTSTAMP:20260403T194244
CREATED:20200330T142019Z
LAST-MODIFIED:20200422T140647Z
UID:3937-1588071600-1588077000@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Inhaled antimicrobials: Do we get the drug to the bug?
DESCRIPTION:Speaker: Harm A. W. M. Tiddens\, Professor of Pediatric Pulmonology and Allergology\, Erasmus Medical Center Sophia Children’s Hospital (Netherlands) \nModerator: Harpal Singh Dhillon\, Global Medical Value Director & Founder\, AntiBx (UK)\n \nIn this webinar\, Harm Tiddens will discuss the relation between structural and functional abnormalities of the lung and how this can impact upon the deposition pattern and efficacy of inhaled antibiotics. He will further present the learnings of his research group’s computational fluid dynamic modelling studies and explain why the expectation that inhaled antibiotics result in high concentrations in the lung is unfortunately a misconception. \nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 28 April\, 17:00-18:30 CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-inhaled-antimicrobials-do-we-get-the-drug-to-the-bug/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200320T090000
DTEND;TZID=America/New_York:20200320T170000
DTSTAMP:20260403T194244
CREATED:20200214T151818Z
LAST-MODIFIED:20200214T151818Z
UID:3792-1584694800-1584723600@carb-x.org
SUMMARY:BAARN2020: Boston Area Antimicrobial Research Network Meeting
DESCRIPTION:The Boston Area Antimicrobial Resistance Network Meeting\, to be held on Friday\, March 20th. \n\nBAARN2020 will be the 7th iteration of this flagship MSI event\, bringing together our collective talents across academia and industry to address the persistent dilemma posed by antimicrobial resistant infection.\n \nTalks will begin at 9 AM in the Northwest Labs Building at 52 Oxford Street\, Cambridge MA 02138\, and our sessions will conclude with the annual Stuart Levy Lecture. A reception will follow at 6 PM at the Harvard Museum of Natural History next door.
URL:https://carb-x.org/event/baarn2020-boston-area-antimicrobial-research-network-meeting/
LOCATION:Harvard Campus\, 52 Oxford Street\, Cambridge\, MA\, 02138\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200227T110000
DTEND;TZID=America/New_York:20200227T123000
DTSTAMP:20260403T194244
CREATED:20200127T163753Z
LAST-MODIFIED:20200127T163906Z
UID:3761-1582801200-1582806600@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - PK/PD murine infection models: Focus on study elements\, variability\, and interpretation of results
DESCRIPTION:In this webinar\, Alexander J. Lepak will review critical study elements that lead to robust preclinical PK/PD results in the murine model. \nTopics discussed will include: \n\nUnderstanding and embracing the inherent variability in many components of the murine model\nDemonstrating how to generate and interpret preclinical murine model PK/PD results\n\nThe presentation will be followed by a Q&A session. \nThe material presented in this webinar was shown but not recorded at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019. \nSpeaker: Alexander J. Lepak\, Assistant Professor\, Department of Medicine\, University of Wisconsin School of Medicine and Public Health (USA) \nModerator: Peter Warn\, Evotec (UK) \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-pk-pd-murine-infection-models-focus-on-study-elements-variability-and-interpretation-of-results/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200204T110000
DTEND;TZID=America/New_York:20200204T123000
DTSTAMP:20260403T194244
CREATED:20200127T162038Z
LAST-MODIFIED:20200127T162038Z
UID:3752-1580814000-1580819400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - Non-traditional antibacterial therapeutic options and challenges
DESCRIPTION:In this webinar\, the following aspects will be presented: \n\nDiscovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline\nThese approaches include anti-virulence strategies\, microbiome-modifying therapies\, phages and others such as nanoparticles\, immunotherapy and drug-resistance modulation\nSome of these approaches require novel preclinical efficacy models to predict clinical outcome\nPathogen-specific or even patient-specific strategies dominate this field\nA major challenge will be to show efficacy in clinical trials\n\nThe presentation will be followed by a Q&A session with Ursula Theuretzbacher and Laura Piddock (GARDP). \nSpeaker: Ursula Theuretzbacher\, CEFAIA\, Austria \nModerator: Prabhavathi Fernandes\, Chair of GARDP’s Scientific Advisory Committee \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-non-traditional-antibacterial-therapeutic-options-and-challenges/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200121T110000
DTEND;TZID=America/New_York:20200121T123000
DTSTAMP:20260403T194244
CREATED:20200127T162345Z
LAST-MODIFIED:20200127T162345Z
UID:3755-1579604400-1579609800@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - Testing for the potential of emergence of antimicrobial resistance
DESCRIPTION:In this webinar\, the following aspects will be presented: \n\nWhat are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques?\nWhat are some techniques that may be used to understand the origins of resistance selection?\nHow to rationalize/manage the risk of translation of the resistance selection from in vitro to the clinical settings?\n\nThe presentation will be followed by a Q&A session. \nThis presentation was also part of the ‘Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process’\, jointly organized by GARDP\, CARB-X\, REPAIR Impact Fund\, JPIMAR and Wellcome Trust at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019.  \n  \nSpeaker: Michael Mourez\, Head BacteriOmics Platform\, Evotec (France) \nModerator: Laura Piddock\, Director Scientific Affairs\, GARDP \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-testing-for-the-potential-of-emergence-of-antimicrobial-resistance/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200121T080000
DTEND;TZID=America/New_York:20200121T170000
DTSTAMP:20260403T194244
CREATED:20200127T163257Z
LAST-MODIFIED:20200127T163257Z
UID:3757-1579593600-1579626000@carb-x.org
SUMMARY:Davos 2020 World Economic Forum - Novo Nordisk Foundation and Novo Holdings: The Broken Model of Antimicrobial resistance
DESCRIPTION:Moderator: Kevin Outterson\, Executive Director\, CARB-X\, Professor of Law\, Boston University \nPanel: \n\nLars Rebien Sorensen\, Chairman of the Novo Nordisk Foundation and Novo Holdings\nJeremy Farrar\, Director\, Wellcome Trust\nDr. Malin Grape\, Head of Antibiotics Unit\, The Public Health Agency of Sweden\nThomas Cueni\, Director General\, IFPMA\nJayasree K. Iyer\, Executive Director\, Access to Medicine Foundation\nFrancesca Colombo\, Head of the Health Division\, OECD\n\nAntimicrobial resistance is one of the biggest threats to human health. The Novo Nordisk Foundation is hosting a session at the World Economic Forum’s Annual Meeting in Davos urging governments\, the biopharma industry and other stakeholders to step up the urgency and respond to the crisis in #antimicrobialresistance with new funding models.  \nTo watch a recording of this panel\, please click here. 
URL:https://carb-x.org/event/davos-2020-world-economic-forum-novo-nordisk-foundation-and-novo-holdings-the-broken-model-of-antimicrobial-resistance/
LOCATION:DAVOS-KLOSTERS\, Switzerland
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200116T103000
DTEND;TZID=America/New_York:20200116T163000
DTSTAMP:20260403T194244
CREATED:20191206T175155Z
LAST-MODIFIED:20191206T175155Z
UID:3653-1579170600-1579192200@carb-x.org
SUMMARY:Exploring Opportunities to Reform Antimicrobial Payment and Post-Market Incentives
DESCRIPTION:Speakers include Kevin Outterson\, Executive Director of CARB-X. \nThe rise of antimicrobial resistance and the corresponding lack of novel antibiotic development impacts the ability of physicians to provide appropriate care for patients. The greatest barriers to a robust antibiotic ecosystem are low return on investment (ROI) and limited market opportunities\, in part due to payment decisions that don’t reflect the value of antibiotics that extends beyond the hospital stay. For years\, policy makers and other stakeholders have been exploring ways to improve the antibiotic ecosystem through development\, regulatory\, and market incentives proposals\, though to date there has been limited impact on manufacturers’ ability to generate adequate ROI. \nThis public meeting will highlight recent actions implemented by stakeholders in the U.S. and globally\, and present additional opportunities to effect change to payment and the costs and returns to antimicrobial investment systems through legislative\, administrative\, and private sector mechanisms.
URL:https://carb-x.org/event/exploring-opportunities-to-reform-antimicrobial-payment-and-post-market-incentives/
LOCATION:Washington Marriott at Metro Center\, 775 12th Street NW\, Washington\, DC\, 20005\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191126T033000
DTEND;TZID=America/New_York:20191126T050000
DTSTAMP:20260403T194244
CREATED:20191031T131530Z
LAST-MODIFIED:20191113T153543Z
UID:3583-1574739000-1574744400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Innovation in point-of-care diagnostics for sepsis and bloodstream infections
DESCRIPTION:In this webinar our moderator Caroline Purslow (Nesta Challenges) will welcome three speakers. \nTill Bachmann (University of Edinburgh) will give an overview of recent advances in AMR diagnostics development. He will discuss: \n\nState of the art approaches for diagnosing infections and AMR\nPipeline of promising tests\nChallenges of adoption\n\nAmrita Sukrity (SpotSense) will draw from her experience as a founder of SpotSense and talk about diagnosis of neonatal sepsis at the community level. Topics discussed will include: \n\nChallenges across diagnosing newborn sepsis in NICU vs. in the community\nIdentifying different phases of sepsis by combining risk parameters and biomarker data\nCreating outlines for biomarker-based differential diagnosis: work ahead\n\nAnd finally\, David Anderson’s (Burnet Institute) presentation ‘CD64 as a host-response biomarker in sepsis and severe infections’ will cover: \n\nLimitations of flow cytometry for CD64 as a diagnostic tool of sepsis and severe infections in emergency situations\nNovel observations on CD64 biology that should facilitate more sensitive a point-of-care (POC) diagnostic tests for sepsis and severe infections\nThe ongoing development of a POC diagnostic test for neutrophil CD64\n\nThe presentations will be followed by a Q&A session. \nRegister here for this live webinar. \nA recording of this webinar will be available on revive.gardp.org/webinars.
URL:https://carb-x.org/event/live-webinar-gardp-revive-innovation-in-point-of-care-diagnostics-for-sepsis-and-bloodstream-infections/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191118
DTEND;VALUE=DATE:20191120
DTSTAMP:20260403T194244
CREATED:20191010T184500Z
LAST-MODIFIED:20191010T184546Z
UID:3517-1574035200-1574207999@carb-x.org
SUMMARY:FDA Workshop: Enhancing the Clinical Trial Enterprise for Antibacterial Drug Development in the United States
DESCRIPTION:Presenters include Kevin Outterson\, Executive Director of CARB-X\, and Erin Duffy\, CARB-X Chief of Research and Development. \nThe FDA\, IDSA\, NIAID and Pew are co-sponsoring this workshop to focus on Enhancing the Clinical Trial Enterprise for Antibacterial Drug Development in the United States. This workshop will bring together a diverse array of subject matter experts in the fields of infectious diseases (ID)\, academics and industry and other government bodies to better understand the current state of U.S. based ID trials and how to enhance enrollment and research in such trials. \nTo learn more\, click here.  \nRegistration:\nThose who are interested in attending this public workshop either in-person or by web viewing must register here by 11:59 pm on November 14\, 2019. Onsite registration will begin at 7:30 am the day of the meeting. Please plan to arrive 30 minutes prior for security processing.
URL:https://carb-x.org/event/fda-workshop-enhancing-the-clinical-trial-enterprise-for-antibacterial-drug-development-in-the-united-states/
LOCATION:FDA White Oak Campus – Building 31\, 10903 New Hampshire Ave\, Silver Spring\, MD\, 20993\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191114
DTEND;VALUE=DATE:20191116
DTSTAMP:20260403T194244
CREATED:20190913T155211Z
LAST-MODIFIED:20191114T171317Z
UID:3425-1573689600-1573862399@carb-x.org
SUMMARY:The 2019 Canada Gairdner Foundation / Ontario International Symposium: Fuelling the Fight against AMR - Global Innovations in Research & Discovery
DESCRIPTION:Kevin Outterson\, Executive Director of CARB-X\, is participating in a special panel discussion titled “When antibiotics fail: An international conversation about the worrisome evidence of impact and what can be done”. During this session\, a panel of international experts will discuss the findings from a new report by the Council of Canadian Academies and discuss what steps can be taken to reduce the impact of rising resistance rates around the world.  Additional panelists include Prof. Andrew Morris\, Prof. Dame Sally Davies\, and Prof. Kathryn Holt. \nAbout the Symposium: \nEach year\, the Gairdner Foundation invites Universities\, Organizations and Research Institutes across Ontario to submit proposals to host a partnered international symposium on the frontiers of biomedicine. \nThis year\, the Michael G. DeGroote Institute for Infectious Disease Research and David Braley Centre for Antibiotic Discovery at McMaster University were honored to have been selected to host the 2019 Gairdner event on the growing global crisis of antimicrobial resistance (AMR). \nDrawing on the Canada Gairdner Awards’ history of recognizing the best in biomedical science\, this symposia will bring leading experts from across the world to present on the state of the international AMR challenge and to showcase recent global advances in AMR research and discovery. \nTo learn more\, click here.  \nTo register\, click here. 
URL:https://carb-x.org/event/the-2019-canada-gairdner-foundation-ontario-international-symposium-fuelling-the-fight-against-amr-global-innovations-in-research-discovery/
LOCATION:McMaster University\, 1280 Main Street W\, Hamilton\, Ontario\, L8S 4L8\, Canada
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20191112T160000
DTEND;TZID=America/Toronto:20191112T190000
DTSTAMP:20260403T194244
CREATED:20191010T184905Z
LAST-MODIFIED:20191010T184905Z
UID:3519-1573574400-1573585200@carb-x.org
SUMMARY:CRISPR and Gene Editing: The New Frontier in Fighting Infectious Diseases?
DESCRIPTION:Presenters include Karen Gallant\, Deputy Executive Director of CARB-X. \nFew technologies have the potential to disrupt and eliminate infectious disease and viral infections– but gene editing\, CRISPR in particular\, is a latent technology that could change biotech – and we’re just seeing the beginning of what effect it could have on the world. \nWith scientific promise comes interest from investors – a surge of biotech startups are utilizing CRISPR technology for many different applications such as at-home testing\, in-clinic uses\, and more. “This incredibly powerful repurposing of the bacterial immune system has created an outpouring of financial backing for small companies with revolutionary technological advancement in genome engineering-based ventures.”[1] \nOn November 12th\, we will explore this subject with presentations from experts in the field\, startup companies innovating in this space\, and investors looking to invest in these new applications. \nTo learn more\, click here. 
URL:https://carb-x.org/event/crispr-and-gene-editing-the-new-frontier-in-fighting-infectious-diseases/
LOCATION:JLabs @ Toronto\, 661 University Ave Suite 1300\, Toronto\, Ontario\, Canada
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191107T110000
DTEND;TZID=America/New_York:20191107T123000
DTSTAMP:20260403T194244
CREATED:20190913T040059Z
LAST-MODIFIED:20190913T154657Z
UID:3423-1573124400-1573129800@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Converting Gram-positive-only compounds into broad-spectrum antibiotics
DESCRIPTION:This webinar by Paul Hergenrother (Department of Chemistry and the Institute for Genomic Biology University of Illinois\, US) will detail his research group’s efforts to understand compound accumulation in the Gram-negative ESKAPE pathogens. Emphasis will be placed on the practicality\, actionability\, and translatability of this information\, specifically\, the use of accumulation rules to convert high-value Gram-positive-only compounds into antibiotics with activity against key Gram-negative pathogens. \nThe presentation will be followed by a Q&A session. \nSpeaker:\nPaul Hergenrother\, Kenneth L. Rinehart Endowed Chair in Natural Products Chemistry\, University of Illinois \nModerator:\nLaura Piddock\, Director of Scientific Affairs\, GARDP \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-converting-gram-positive-only-compounds-into-broad-spectrum-antibiotics/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191107
DTEND;VALUE=DATE:20191109
DTSTAMP:20260403T194244
CREATED:20190923T194433Z
LAST-MODIFIED:20190923T194433Z
UID:3461-1573084800-1573257599@carb-x.org
SUMMARY:World Anti-Microbial Resistance Congress 2019
DESCRIPTION:Kevin Outterson\, Executive Director of CARB-X\, will be giving the keynote Address on November 7th\, titled “A vision for a health antibiotic R&D ecosystem”.  Outterson will also be participating on a panel titled “Analyzing the potential impact of current commercial and “pull” initiatives” on November 7th. \nKaren Gallant\, Deputy Executive Director of CARB-X\, will be presenting on November 7th on “Accelerating innovation to fight drug-resistant bacteria”. \nAbout the World AMR Congress:\nSince 2015\, the World Anti-Microbial Resistance Congress has been the only commercially focused conference globally of its kind.  Launched during the release of key reports such as the AMR Review and A Scientific Roadmap for Antibiotic Discovery\, the World AMR Congress has brought attention to the threats of this emerging crisis to the global healthcare system. The conference gathers global leaders in infectious diseases to meet\, brainstorm and discuss the challenges and opportunities on seven topic areas: \n\nAntibiotic R&D: advancing the development of antibiotic and non-traditional therapies and improving commercialization strategies\nDiagnostics: innovating the development and deployment of rapid diagnostics tests\, while ensuring an effective integration into hospitals’ workflow and reimbursement\nAntimicrobial stewardship: using technology to improve antibiotic prescription\, monitoring and surveillance while advancing stewardship-based purchasing guidelines\nPitch & Partner: joining funding and partnerships with antibiotics and diagnostics innovation\nInfection Control: advancing policies to improve infection prevention\, control and compliance in healthcare facilities\nManufacturing: overcoming challenges for a sustainable and controlled antibiotic manufacturing and supply chain\nVaccines: discussing the clinical and economic value of vaccines to combat AMR\n\nTo learn more\, click here. \nTO view the agenda\, click here. \nTo register\, click here.
URL:https://carb-x.org/event/world-anti-microbial-resistance-congress-2019/
LOCATION:Renaissance Washington DC Downtown Hotel\, 999 9th St NW\, Washington\, DC\, 20001\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191104T160000
DTEND;TZID=America/New_York:20191104T180000
DTSTAMP:20260403T194244
CREATED:20191022T143433Z
LAST-MODIFIED:20191022T143453Z
UID:3542-1572883200-1572890400@carb-x.org
SUMMARY:Challenges in Antimicrobial Resistance - A Conversation with Kevin Outterson
DESCRIPTION:Kevin Outterson\, Executive Director of CARB-X\, will be speaking at the Harvard Chan School of Public Health. \nThis presentation is sponsored by Harvard Antimicrobial Resistance (HAMR) a subgroup of the Harvard Infectious Diseases Consortium. \n\n\n\n\nFor more information\, visit harvardamr.com   \n\n\n\n\n 
URL:https://carb-x.org/event/challenges-in-antimicrobial-resistance-a-conversation-with-kevin-outterson/
LOCATION:Harvard Chan School of Public Health\, 677 Huntington Ave FXB 301\, Boston\, MA\, 02115\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191019
DTEND;VALUE=DATE:20191028
DTSTAMP:20260403T194244
CREATED:20190201T201331Z
LAST-MODIFIED:20191018T153826Z
UID:2292-1571443200-1572220799@carb-x.org
SUMMARY:Institut Pasteur - International Course on Antibiotics and Resistance (ICARE)
DESCRIPTION:Speakers include Erin Duffy\, CARB-X Chief of Research and Development. \nThe emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is currently no course providing advanced instruction on antibiotics and resistance. The specific goal of ICARe is to bring leaders in academics and industry together with trained scientists at the dawn of their careers. Cutting-edge approaches for detection of resistance and antibiotic discovery\, chemical optimization\, and usage that minimizes the development of resistance will be examined. \nThe objective of the course is to train the next generation of scientists implicated in the study of bacterial resistance to antibiotics and the finding of new drugs. The faculty is composed of 40 internationally recognized scientists and physicians who have made important contributions to antibiotic development\, and infectious diseases and resistance management. Faculty will be in residence for a minimum of two days and accessible for informal interactions. Graduates will emerge with a state-of-the-art understanding of existing antibiotics: modes of action\, pharmacology\, toxicology\, mechanisms of resistance\, impact of antibiotics on human and other ecologies\, current approaches for mining chemical space for antimicrobial activity\, the process of advancing hits to leads\, the application of next generation nucleic acid-based technologies for antibiotic discovery and resistance detection\, and perhaps\, most importantly\, training and experience in thinking creatively and innovatively about solutions to the problem. The course aims to build an international cadre of collaborative\, well networked\, and highly trained specialists. \nTo learn more\, click here. \nTo register for the course\, please click here. \nPlease note that registration is currently open and will close on May 17th.
URL:https://carb-x.org/event/institut-pasteur-international-course-on-antibiotics-and-resistance-icare/
LOCATION:Les Pensieres\, Annecy\, France
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191011T120000
DTEND;TZID=America/New_York:20191011T130000
DTSTAMP:20260403T194244
CREATED:20190923T195010Z
LAST-MODIFIED:20190926T124915Z
UID:3463-1570795200-1570798800@carb-x.org
SUMMARY:Live Webcast: Drug-Resistant Infections: Confronting an Escalating Crisis
DESCRIPTION:Antibiotics are a pillar of modern medicine. They have saved millions of lives and added some 20 years to human life expectancy. But as the use of antibiotics has increased\, so has the proliferation of antibiotic-resistant microbes that have adapted to survive most\, or all\, of today’s antibiotics. The CDC reports that two million people are infected with drug-resistant bacteria every year in the United States\, and the Review on Antimicrobial Resistance estimated that\, around the world\, 700\,000 people die of such infections annually. That number stands to increase: the Review predicts that\, by 2050\, drug resistance could be responsible for 10 million deaths a year. And while these numbers are dominated by bacterial infections\, fungal infections like Candida auris are also a threat\, especially to vulnerable patients in hospitals and nursing homes. \nDespite drug resistance growing\, the development of new antibiotics has slowed. How can policymakers help accelerate the pace of new drug development. How can all of us—doctors\, hospitals\, and patients\, as well as the agricultural sector—be better stewards of existing drugs? Forum panelists will examine the scope of this looming crisis and look at how changes in policy and practice can help us stay one step ahead of these superbugs. \nModerator\nDavid Freeman\, Editorial Director of NBC News MACH \nPanelists\nHelen Boucher\, Director\, Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR) and Professor of Medicine at Tufts University School of Medicine \nLauri Hicks\, Director\, Office of Antibiotic Stewardship\, Centers for Disease Control and Prevention \nMarc Lipsitch\, Professor of Epidemiology and Director of the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health \nKevin Outterson\, Executive Director of CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator)\, and Professor of Law\, Boston University \nPart of: The Dr. Lawrence H. and Roberta Cohn Forums.\nPresented jointly with NBC News Digital \nLive webcast will be on Friday\, October 11\, 2019\, 12:00pm – 1:00pm ET.\nAn on-demand video will be posted after the event. \nTo learn more\, click here.
URL:https://carb-x.org/event/live-webcast-drug-resistant-infections-confronting-an-escalating-crisis/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191003T110000
DTEND;TZID=America/New_York:20191003T123000
DTSTAMP:20260403T194244
CREATED:20190729T133232Z
LAST-MODIFIED:20190729T133501Z
UID:3229-1570100400-1570105800@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Natural products antibiotics: from traditional screening to novel discovery approaches
DESCRIPTION:In this webinar\, Olga Genilloud will discuss the role of natural products in current antibiotic discovery. Topics discussed will include: \n\nScreening strategies to identify novel antibiotics\nCurrent challenges and novel analytical tools\nNew omic approaches supporting antibiotic discovery\n\nThe presentation will be followed by a Q&A session. \n  \nSpeaker: \nOlga Genilloud\, Scientific Director\, Fundación MEDINA\, Granada\, Spain \nModerator: \nLaura Piddock\, Director of Scientific Affairs\, GARDP \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-natural-products-antibiotics-from-traditional-screening-to-novel-discovery-approaches/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191002
DTEND;VALUE=DATE:20191007
DTSTAMP:20260403T194244
CREATED:20190201T201142Z
LAST-MODIFIED:20190528T161659Z
UID:2290-1569974400-1570406399@carb-x.org
SUMMARY:IDWeek 2019 Annual Conference
DESCRIPTION:Attendees include Richard Alm\, CARB-X Alliance Director. \nIDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA)\, Society for Healthcare Epidemiology of America (SHEA)\, the HIV Medical Association (HIVMA)\, and the Pediatric Infectious Diseases Society (PIDS). \nAt IDWeek\, you will see familiar colleagues and new faces. IDWeek is a forum for health professionals of varied backgrounds to collaborate\, cooperate\, and learn from each other’s expertise. With so many common issues and challenges cutting across our four disciplines\, IDWeek provides an opportunity to learn from each other’s knowledge\, experience and expertise\, for the improvement of patient care and public health. \nThis is an inclusive meeting that offers access to internationally recognized leaders in the field and the opportunity to network with the most highly respected health professionals in infectious diseases\, including HIV. \nTo learn more\, click here. \nTo view the program\, click here. \nTo register for the conference\, click here.
URL:https://carb-x.org/event/idsas-annual-idweek-meeting/
LOCATION:Walter E. Washington Convention Center\, 801 Mount Vernon Pl. NW\,\, Washington D.C.\, DC\, 20001\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190923T180000
DTEND;TZID=America/New_York:20190923T210000
DTSTAMP:20260403T194244
CREATED:20190813T163022Z
LAST-MODIFIED:20190813T163022Z
UID:3280-1569261600-1569272400@carb-x.org
SUMMARY:AMR Challenge: A Night Celebrating Global AMR Fighters
DESCRIPTION:Join HHS Secretary\, Alex Azar\, experts from the U.S. Centers for Disease Control and Prevention\, and hundreds of organizational and global leaders for an evening celebrating the culmination of the AMR Challenge at an unofficial side event of the 74th United Nations General Assembly in New York City.
URL:https://carb-x.org/event/amr-challenge-a-night-celebrating-global-amr-fighters/
LOCATION:Cipriani Midtown\, 110 E. 42nd Street\, New York City\, NY\, 10017\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190910T110000
DTEND;TZID=America/New_York:20190910T123000
DTSTAMP:20260403T194244
CREATED:20190729T132915Z
LAST-MODIFIED:20190729T133433Z
UID:3226-1568113200-1568118600@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research
DESCRIPTION:In this webinar\, Peter Warn will review the experimental design and conduct of advanced or complex animal models for antimicrobial research. \nThis webinar is designed as a follow on from the webinar of William J. Weiss: Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research (see here: http://bit.ly/2ZiPt6y). \nTopics covered in this webinar will include: \n\nIn depth review of animal models of pneumonia\, UTI and tissue infections including biofilm models.\nAnimal models of non-traditional drugs where CFU might not be a suitable biomarker.\nTips\, hints and pitfalls when trying to generate informative data in PKPD studies.\n\nThe presentation will be followed by a Q&A session. \n  \nSpeaker: \nPeter Warn\, Senior Vice President\, Anti-infective Discovery\, Evotec \nModerator: \nWilliam J. Weiss\, Director\, PreClinical Services\, University of North Texas System College of Pharmacy \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-models-for-antimicrobial-rd-advanced-and-complex-in-vivo-models-for-infectious-disease-research/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
END:VCALENDAR